专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20210346397A1 MULTIPHASIC CONTRACEPTIVE REGIMEN FOR ORAL COMBINATION DRUG FORMULATION OF PROGESTIN AND ESTROGEN 有权
公开(公告)号：US20210346397A1
公开(公告)日：2021-11-11
申请号：US17385330
申请日：2021-07-26
申请人： Arkady Rubin
发明人： Arkady RUBIN
IPC分类号： A61K31/567 , A61K31/57 , A61K31/565 , A61K9/00
摘要： A method for contraception includes administering to a female daily, in a triphasic dosing regimen during a time period of 21 successive days, an oral combination drug formulation of levonorgestrel (LNG) and ethinyl estradiol (EE), wherein doses in the second, third and fourth phases of the regimen increase by a predefined dose increment as compared to the corresponding doses administered during the previous phase, wherein the LNG dose in the first phase is 100 mcg, in the second phase is 125 mcg, and in the third phase is 150 mcg, wherein the EE dose in the first phase is 20 mcg, in the second phase is 25 mcg, and in the third phase is 30 mcg, and wherein the triphasic dosing regimen is followed by 7 days without LNG and EE administration.

2. 发明申请

US20140256690A1 CONTRACEPTIVE METHOD 审中-公开
标题翻译：承办方式
公开(公告)号：US20140256690A1
公开(公告)日：2014-09-11
申请号：US14201153
申请日：2014-03-07
申请人： Arkady RUBIN , Maria FOEGH , Agis KYDONIEUS , Thomas M. ROSSI
发明人： Arkady RUBIN , Maria FOEGH , Agis KYDONIEUS , Thomas M. ROSSI
IPC分类号： A61K9/70 , A61K31/565 , A61K31/567
CPC分类号： A61K31/565 , A61K9/7061 , A61K31/567 , A61K2300/00
摘要： A transdermal drug delivery device for reducing the risk of pregnancy in overweight women is disclosed. Methods of using the device are also disclosed. When used in accordance with the disclosed methods, the probability that the device will be effective in overweight women is approximately equal to or greater than the probability that the device would be effective in the case of a woman who is not overweight.
摘要翻译：公开了一种用于降低超重女性怀孕风险的透皮给药装置。还公开了使用该装置的方法。当根据所公开的方法使用时，设备在超重女性中有效的可能性大约等于或大于在不超重的女性的情况下该装置有效的概率。

3. 发明授权

US06214815B1 Triphasic oral contraceptive 有权
标题翻译：三相口服避孕药
公开(公告)号：US06214815B1
公开(公告)日：2001-04-10
申请号：US09328764
申请日：1999-06-09
申请人： Gary Shangold , Arkady Rubin , David Upmalis
发明人： Gary Shangold , Arkady Rubin , David Upmalis
IPC分类号： A61K3156
CPC分类号： A61K31/565 , A61K31/57 , A61K2300/00
摘要： A method of contraception in which an estrogen and a progestogen are administered daily in a three phase sequence for 21 days is disclosed. In the first phase a combination of an estrogen and a progestogen in a low but contraceptively effective daily dosage corresponding in estrogenic activity to 23-28 &mgr;g of 17&agr;-ethinylestradiol and in progestogenic activity to 0.065-0.75 mg of norethindrone is administered for 5-8 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0.25-1.0 mg of norethindrone for 7-11 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0.35-2.0 mg of norethindrone for 3-7 days; followed by 4-8 days without administering either an estrogen or a progestogen.
摘要翻译：公开了一种避孕方法，其中雌激素和孕激素每天以三相序列施用21天。在第一阶段，雌激素和孕激素在雌激素活性较低但避孕有效的日剂量中与23-28杯17α-炔雌醇和孕激素活性至0.065-0.75毫克炔诺酮的组合施用于5-8 天; 随后将相同剂量的孕激素和孕激素相应于孕激素活性给予0.25-1.0毫克炔诺酮7-11天; 然后将相同剂量的雌激素和孕激素相应的孕激素施用于0.35-2.0mg炔诺酮3-7天; 随后4-8天，不给予雌激素或孕激素。

4. 发明授权

US12005138B2 Treatment of endometriosis by intravaginal administration of a low dose of a selective progesterone receptor modulator (SPRM), anti-progestin, or anti-progestational agent 有权
公开(公告)号：US12005138B2
公开(公告)日：2024-06-11
申请号：US17401964
申请日：2021-08-13
申请人： Arkady Rubin
发明人： Arkady Rubin
IPC分类号： A61K9/00 , A61K31/569 , A61K31/57 , A61K31/575 , A61P15/02
CPC分类号： A61K9/0036 , A61K9/0039 , A61K31/569 , A61K31/57 , A61K31/575 , A61P15/02
摘要： An intravaginal drug delivery device comprising: a drug delivery device, and a therapeutically effective amount of a single active agent that is therapeutically effective for the treatment of endometriosis, wherein the drug delivery device delivers the single active agent directly to endometrial implants in women diagnosed with endometriosis, wherein the single active agent is selected from the group consisting of mifepristone and metabolites thereof.

5. 发明授权

US11717527B2 Multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogen 有权
公开(公告)号：US11717527B2
公开(公告)日：2023-08-08
申请号：US17385330
申请日：2021-07-26
申请人： Arkady Rubin
发明人： Arkady Rubin
IPC分类号： A61K31/567 , A61K31/57 , A61K31/565 , A61K9/00
CPC分类号： A61K31/567 , A61K9/0053 , A61K31/565 , A61K31/57 , A61K31/567 , A61K2300/00 , A61K31/57 , A61K2300/00
摘要： A method for contraception includes administering to a female daily, in a triphasic dosing regimen during a time period of 21 successive days, an oral combination drug formulation of levonorgestrel (LNG) and ethinyl estradiol (EE), wherein doses in the second, third and fourth phases of the regimen increase by a predefined dose increment as compared to the corresponding doses administered during the previous phase, wherein the LNG dose in the first phase is 100 mcg, in the second phase is 125 mcg, and in the third phase is 150 mcg, wherein the EE dose in the first phase is 20 mcg, in the second phase is 25 mcg, and in the third phase is 30 mcg, and wherein the triphasic dosing regimen is followed by 7 days without LNG and EE administration.

6. 发明申请

US20210369606A1 TREATMENT OF ENDOMETRIOSIS BY INTRAVAGINAL ADMINISTRATION OF A LOW DOSE OF A SELECTIVE PROGESTERONE RECEPTOR MODULATOR (SPRM), ANTI-PROGESTIN, OR ANTI-PROGESTATIONAL AGENT 有权
公开(公告)号：US20210369606A1
公开(公告)日：2021-12-02
申请号：US17401964
申请日：2021-08-13
申请人： Arkady Rubin
发明人： Arkady RUBIN
IPC分类号： A61K9/00 , A61K31/575 , A61P15/02 , A61K31/569 , A61K31/57
摘要： An intravaginal drug delivery device comprising: a drug delivery device, and a therapeutically effective amount of a single active agent that is therapeutically effective for the treatment of endometriosis, wherein the drug delivery device delivers the single active agent directly to endometrial implants in women diagnosed with endometriosis, wherein the single active agent is selected from the group consisting of mifepristone and metabolites thereof.

7. 发明申请

US20050038006A1 Triphasic oral contraceptive 审中-公开
标题翻译：三相口服避孕药
公开(公告)号：US20050038006A1
公开(公告)日：2005-02-17
申请号：US10945698
申请日：2004-09-21
申请人： Gary Shangold , Arkady Rubin , David Upmalis
发明人： Gary Shangold , Arkady Rubin , David Upmalis
IPC分类号： A61K31/565 , A61K31/57 , A61K31/56
CPC分类号： A61K31/565 , A61K31/57 , A61K2300/00
摘要： A method of contraception in which an estrogen and desogestrel are administered daily in a three phase sequence for 21 days is disclosed. In the first phase a combination of an estrogen and a progestogen in a low but contraceptively effective daily dosage corresponding in estrogenic activity to 23-28 μg of 17α-ethinylestradiol and in progestogenic activity to 0.065-0.75 of norethindrone is administered for 5-8 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0.25-1.0 mg of norethindrone for 7-11 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0.35-2.0 mg of norethindrone for 3-7 days; followed by 4-8 days without administering either an estrogen or a progestogen, provided that the progestin dose should increase from the first phase to the second phase to the third phase, that the progestin is desogestrel at a dose in each phase of between of from 0.05-1.0 mg/day and that the dosage of estrogen is kept constant in each phase.
摘要翻译：公开了一种避孕方法，其中雌激素和去氧孕烯每天以三相序列施用21天。在第一阶段中，雌激素和孕激素在雌激素活性较低但避孕有效的日剂量中与23-28杯17α-炔炔雌二醇和孕激素活性至0.065-0.75的炔诺酮的组合施用5-8天 ; 随后将相同剂量的孕激素和孕激素相应于孕激素活性给予0.25-1.0毫克炔诺酮7-11天; 然后将相同剂量的雌激素和孕激素相应的孕激素施用于0.35-2.0mg炔诺酮3-7天; 随后4-8天，不给予雌激素或孕激素，条件是孕激素剂量应从第一阶段增加至第二阶段至第三阶段，孕激素以每个阶段的剂量在去氧孕烯之间 0.05-1.0mg /天，雌激素剂量在每个阶段保持不变。

8. 发明公开

US20230330108A1 MULTIPHASIC CONTRACEPTIVE REGIMEN FOR ORAL COMBINATION DRUG FORMULATION OF PROGESTIN AND ESTROGEN 审中-公开
公开(公告)号：US20230330108A1
公开(公告)日：2023-10-19
申请号：US18336476
申请日：2023-06-16
申请人： Arkady Rubin
发明人： Arkady RUBIN
IPC分类号： A61K31/567 , A61K31/57 , A61K31/565 , A61K9/00
CPC分类号： A61K31/567 , A61K31/57 , A61K31/565 , A61K9/0053
摘要： A method for contraception includes administering to a female daily, in a triphasic dosing regimen during a time period of 21 successive days, an oral combination drug formulation of norethindrone acetate and ethinyl estradiol (EE), wherein doses in the second, third and fourth phases of the regimen increase by a predefined dose increment as compared to the corresponding doses administered during the previous phase, wherein the norethindrone acetate dose in the first phase is 1000 mcg, in the second phase is 1250 mcg, and in the third phase is 1500 mcg, wherein the EE dose in the first phase is 20 mcg, in the second phase is 25 mcg, and in the third phase is 30 mcg, and wherein the triphasic dosing regimen is followed by 7 days without norethindrone acetate and EE administration.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式